collection
https://read.qxmd.com/read/37581186/guidance-document-risk-assessment-of-patients-with-cirrhosis-prior-to-elective-non-hepatic-surgery
#1
JOURNAL ARTICLE
Nadir Abbas, Jonathan Fallowfield, David Patch, Adrian J Stanley, Raj Mookerjee, Emmanouil Tsochatzis, Joanna A Leithead, Peter Hayes, Abhishek Chauhan, Vikram Sharma, Neil Rajoriya, Simon Bach, Thomas Faulkner, Dhiraj Tripathi
As a result of the increasing incidence of cirrhosis in the UK, more patients with chronic liver disease are being considered for elective non-hepatic surgery. A historical reluctance to offer surgery to such patients stems from general perceptions of poor postoperative outcomes. While this is true for those with decompensated cirrhosis, selected patients with compensated early-stage cirrhosis can have good outcomes after careful risk assessment. Well-recognised risks include those of general anaesthesia, bleeding, infections, impaired wound healing, acute kidney injury and cardiovascular compromise...
2023: Frontline Gastroenterology
https://read.qxmd.com/read/37151186/infections-in-inflammatory-bowel-disease-patients-on-immunomodulator-and-biologic-therapy-are-not-associated-with-high-serum-drug-levels
#2
JOURNAL ARTICLE
Kathryn Gazelakis, Isabel Chu, Catherine Martin, Miles P Sparrow
BACKGROUND: Inflammatory bowel disease (IBD) therapies now utilise higher doses of immunomodulatory and biologic therapies, predisposing patients to an increased risk of infections. AIMS: We aimed to determine whether infections were associated with high anti-tumour necrosis factor (TNF) drug levels in IBD and to quantify the risk and consequences of infections. METHODS: Two retrospective studies were performed, a descriptive cohort study and a matched case-control study...
May 7, 2023: Internal Medicine Journal
https://read.qxmd.com/read/22287700/medical-management-of-hepatorenal-syndrome
#3
REVIEW
Andrew Davenport, Jawad Ahmad, Ali Al-Khafaji, John A Kellum, Yuri S Genyk, Mitra K Nadim
Hepatorenal syndrome (HRS) is defined as the occurrence of renal dysfunction in a patient with end-stage liver cirrhosis in the absence of another identifiable cause of renal failure. The prognosis of HRS remains poor, with a median survival without liver transplantation of <6 months. However, understanding the pathogenesis of HRS has led to the introduction of treatments designed to increase renal perfusion and mean arterial blood pressure using vasopressors and albumin, which has led to improvement in renal function in ∼50% of patients...
January 2012: Nephrology, Dialysis, Transplantation
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.